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DOI 10.1016/j.ccr.2010.03.022SUMMARYDominant RUNX1 inhibition has been proposed as a common pathway for CBF leukemia. CBFb-SMMHC,
a fusion protein in human acute myeloid leukemia (AML), dominantly inhibits RUNX1 largely through its
RUNX1 high-affinity binding domain (HABD). However, the type I CBFb-SMMHC fusion in AML patients lacks
HABD. Here, we report that the type I CBFb-SMMHC protein binds RUNX1 inefficiently. Knockin mice
expressing CBFb-SMMHC with a HABD deletion developed leukemia quickly, even though hematopoietic
defects associated with Runx1-inhibition were partially rescued. A larger pool of leukemia-initiating cells,
increased MN1 expression, and retention of RUNX1 phosphorylation are potential mechanisms for acceler-
ated leukemia development in these mice. Our data suggest that RUNX1 dominant inhibition may not be a
critical step for leukemogenesis by CBFb-SMMHC.INTRODUCTION
A chromosome 16 inversion, inv(16)(p13q22), is associated
with almost all cases of human acute myeloid leukemia (AML)
subtype M4Eo (Liu et al., 1995). A chimeric gene CBFB–
MYH11 is generated by this inversion, which encodes a fusion
protein between CBFb and smooth muscle myosin heavy
chain (SMMHC) (Liu et al., 1993). In a knockin mouse model
CBFb-SMMHC blocks embryonic definitive hematopoiesis as
well as differentiation of adult hematopoietic stem cells (HSCs)
to myeloid and lymphoid lineages (Castilla et al., 1996). ThisSignificance
CBFb-SMMHC is a common mutation in human AML and is ca
Dominant repression of RUNX1 has been considered as the m
leukemogenesis is unclear. One of the ten CBFB-MYH11 fus
not bind or repress RUNX1 efficiently, suggesting that domin
CBFB-MYH11. We generated knockin mice expressing a dele
and inhibition. The contrasting phenotype of partial hemato
that the ability of CBFb-SMMHC to induce leukemia does notphenotype is similar to those in the Runx1/ or Cbfb/ mice
(Okuda et al., 1996; Wang et al., 1996), suggesting that CBFb-
SMMHC is a dominant repressor of RUNX1/CBFb function.
Furthermore, mutagenesis studies using Cbfb+/MYH11 knockin
mice indicated that CBFb-SMMHC is necessary, but not
sufficient, for leukemogenesis; additional genetic events are
required (Castilla et al., 1999, 2004).
Normally, CBFb binds to RUNX1 via its heterodimerization
interface (Warren et al., 2000), which is retained in CBFb-
SMMHC. Moreover, the fusion between the coiled-coil rod
region of SMMHC and CBFb creates a novel binding site forusally related to leukemogenesis in a knockin mouse model.
ain function of CBFb-SMMHC; however, its importance in
ions detected in AML patients also lacks HABD and does
ant RUNX1 inhibition is not critical for leukemogenesis by
tion mutant of CBFb-SMMHC with reduced RUNX1 binding
poiesis rescue and accelerated leukemogenesis suggests
correlate with its ability to repress RUNX1.
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Leukemogenesis by Truncated CBFb-SMMHCRUNX1, called the RUNX1 high-affinity binding domain (HABD)
(Lukasik et al., 2002). As a result, CBFb-SMMHC binds RUNX1
at two sites, which is associated with higher binding affinity.
This high-affinity RUNX1 binding has been proposed to explain
the dominant nature of CBFb-SMMHC function over wild-type
CBFb (Lukasik et al., 2002).
Clinically, ten different types of CBFb-SMMHC fusion can be
produced by the chromosome 16 inversion, mainly due to the
variation of inversion breakpoint locations in the MYH11 gene
(van Dongen et al., 1999). Nine of the ten fusion types contain
the HABD. However, one fusion type, type I, which contains
the shortest fragment of SMMHC among all ten fusion types,
does not contain the HABD. We decided to study this fusion
type and a similar deletion construct to determine if HABD is
required for leukemogenesis by CBFb-SMMHC.RESULTS
Type I CBFb-SMMHC Has Highly Reduced Binding
Affinity for RUNX1
The type I CBFB-MYH11 fusion junction results in the deletion of
amino acids 134 through 236 of the CBFb-SMMHC protein
(CBFb-SMMHCd134-236) (Dissing et al., 1998; Van der Reijden
et al., 2001). The deletion encompasses the entire HABD (amino
acids [aa] 179 through 221) as well as the sequence encoded by
Cbfb exon 5 (Figure 1A), which results in the deletion of a signif-
icant segment of the C-terminal helix in the CBFb portion of the
fusion protein (aa 134–138). A deletion in this helix will likely
disrupt the fold of CBFb, which is predicted to result in severe
reduction in RUNX1 binding.
We used isothermal titration calorimetry (ITC) to measure
the binding affinity of CBFb-SMMHCd134-236 with RUNX1
(Figure 1B). Fitting the ITC measurements for binding of
CBFb-SMMHCd134-236 to the runt domain of RUNX1 yielded a
1:1 stoichiometry (n = 1.17) and a Kd of 709 (±47) nM. The
stoichiometry is in agreement with our previous measurements
of a similar HABD-deletion construct, CBFb-SMMHCd179-221,
as well as measurements of the wild-type CBFb, but differs
from that of full-length CBFb-SMMHC, which is 2:1 (Lukasik
et al., 2002). The binding affinity data suggest a significant loss
of binding affinity, because the Kd for CBFb-SMMHCd134-236
binding to RUNX1 is 100-fold weaker than full-length CBFb-
SMMHC (7 nM), 20-fold weaker than CBFb-SMMHCd179-221
(34 nM), and even13-fold weaker than wild-type CBFb (54 nM).CBFb-SMMHC without HABD Is Less Efficient Than
Full-Length CBFb-SMMHC for Repressing RUNX1
We previously reported that CBFb-SMMHC represses RUNX1
function in CD4 silencing and restores CD4 promoter transcrip-
tional activity in a reporter assay (Zhao et al., 2007). We tested
CBFb-SMMHCd179-221 and CBFb-SMMHCd134-236 in this
reporter assay (Figure 1C). As we described before, in the
presence of full-length CBFb-SMMHC (FL), CD4-CAT activity
was significantly restored when compared with those with
CD4 silencer (p131-265) alone or in the presence of RUNX1.
CBFb-SMMHCd179-221 (d179-221) and CBFb-SMMHCd134-236
(d134-236) could partially restore CD4-CAT activity but
were much less efficient than full-length CBFb-SMMHC (FL)456 Cancer Cell 17, 455–468, May 18, 2010 ª2010 Elsevier Inc.(p < 0.05). CBFb-SMMHCd134-236 was the weakest, which
correlated with its inability to bind RUNX1 efficiently.
We also performed reporter assay in which the expression of
luciferase was driven by the macrophage colony-stimulating factor
(M-CSF) receptor promoter (Rhoades et al., 1996). As can be seen
in Figure 1D, full-length CBFb-SMMHC repressed this reporter
activity, which was activated synergistically by RUNX1 and
CBFb. On the other hand, both CBFb-SMMHCd179-221 and CBFb-
SMMHCd134-236 variants partially restored the reporter activity.
Figures 1E and F are representative western blot data showing
the expression levels of the transfected constructs in these two
reporter assays, respectively.
Generation of Knockin Mice Expressing
HABD-Truncated CBFb-SMMHC
We generated mouse ESC lines expressing truncated CBFb-
SMMHC that lacks only the HABD (CBFb-SMMHCd179-221). The
knockin strategy is shown in Figure 2A, and is similar to what we
reported previously (Castilla et al., 1996) with the exception that
the selection marker gene, neo, is flanked by two lox-P sites.
Aknockinconstruct for the full-lengthCBFb-SMMHCwithafloxed
neo cassette was also made as a control. Targeted ESC clones
were identified by Southern blot hybridization (Figure 2B). The
expression of the fusion proteins from each targeted ESC line
wasconfirmed bywesternblot (Figure 2C). We produced chimeric
mice using two independent Cbfb-MYH11d179-221 knockin ESC
clones (no. 220, no. 269) and one full-lengthCbfb-MYH11knockin
ESC clone (no. 10), which served as a positive control. The
chimeras from all three lines had successful germ-line transmis-
sion. The chimeras and F1 mice from the two independent
Cbfb-MYH11d179-221 knockin clones had identical phenotypes.
Partial Phenotypic Rescue in Embryos Heterozygous
for Cbfb-MYH11d179-221 Knockin
Two Cbfb+/MYH11d179-221 F1 mice were born alive, among 25
newborn mice observed (8%) (Figure 3A), suggesting decreased
survival but significantly different from Cbfb+/MYH11 F1 mice,
which never survived to birth (Castilla et al., 1996). Further
studies showed that at E12.5, mostCbfb+/MYH11d179-221 embryos
developed multiple hemorrhages in the central nervous system,
as seen in Cbfb+/MYH11 embryos (Castilla et al., 1996). However,
several Cbfb+/MYH11d179-221 embryos remained alive after E13.5
(Figure 3A), and one Cbfb+/MYH11d179-221 embryo had no hemor-
rhage at E16.5, whereas all Cbfb+/MYH11 embryos died at E13.5
(Castilla et al., 1996).
The livers of the E12.5–13.5 Cbfb+/MYH11d179-221 embryos
looked paler than those of the wild-type littermates but not as
severe as in the Cbfb+/MYH11 embryos (data not shown). Histo-
logically, hematopoietic progenitors were clearly visible in the
liver sections of the Cbfb+/MYH11d179-221 embryos, in contrast to
those in Cbfb+/MYH11 embryos, which contained no hematopoi-
etic progenitors (Figures 3B–3D). Megakaryocytes were
observed in the liver of the Cbfb+/MYH11d179-221 embryos, even
though in reduced numbers, contrary to Cbfb+/MYH11 fetal livers
where there were no megakaryocytes (Figures 3B–3D). In vitro
colony-forming assay was then used to assess fetal liver
hematopoiesis in the Cbfb+/MYH11d179-221 embryos. CFU-M,
CFU-GM, CFU-GEMM, and total colony numbers were signifi-
cantly reduced when compared with the wild-type littermates
Figure 1. The Type I CBFb-SMMHC Fusion Variant Is Very Inefficient in Binding and Repressing RUNX1
(A) Diagrammatic representation of CBFb-SMMHC fusion variants. CBFb-SMMHCd134-236, generated by type I fusion, misses the HABD as well as CBFb residues
encoded by exon 5. CBFb-SMMHCd179-221 misses only the HABD and has been described before (Lukasik et al., 2002).
(B) ITC measurement of interactions between 200 mM CBFb-SMMHCd134-236 and 7.5 ml injections of 15 mM RUNX1 Runt domain. The top panel shows the raw
data, whereas the bottom panel is a plot of the binding corrected for the dilution enthalpy (average dilution enthalpy = 232 cal mol1). Data were fit to a one-site
binding model. The results of a fit to one titration are shown in the box at the lower right corner. The average Kd of two independent experiments is 709 (±47) nM.
(C) CD4 reporter assay. E4P4: CD4 enhancer and promoter; P131-265: core sequence of CD4 repressor; FL: CBFb-SMMHC; d179-221: CBFb-SMMHCd179-221;
d134-236: CBFb-SMMHCd134-236. D: statistically significant difference (p < 0.05) between the top two conditions, which are P131-265 + Runx1 with either
d179-221 or d134-236. *Statistically significant differences (p < 0.05) between the top two conditions and the third one, which is P131-265 + Runx1 + FL.
(D) MCSFR reporter assay. pMCSFR: the luciferase reporter driven by human MCSFR promoter.
(E and F) Western blot analysis showing the expression of the transfected constructs in the reporter assays (C and D, respectively). The expression of CBFb
and full-length and variant CBFb-SMMHC constructs was detected with a mouse monoclonal antibody (b141.2) specific for CBFb. The error bars in (C) and
(D) represent one standard deviation (SD).
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Figure 2. Generation of Mouse ESC Lines
with Cbfb-MYH11d179-221 and Full-Length
Cbfb-MYH11 Knockin Constructs
(A) Targeting strategy used to replace exon5 of
Cbfb with the targeting constructs. Location of
probe 0.2C and the sizes of NcoI fragments de-
tected by 0.2C are indicated. The arrows indicate
the locations of PCR primers used for genotyping.
Filled triangles represent lox-P sites.
(B) Southern blot hybridization of NcoI-digested
DNA from the parental ESCs (TC1; lanes 1, 3,
and 5) and the targeted ESC clones (lane 2: clone
no. 10 for Cbfb-MYH11; lanes 4 and 6: clones no.
220 and no. 269 for Cbfb-MYH11d179-221) with
probe 0.2C. The 15.7 kb band corresponds to
the wild-type Cbfb allele, and the 6.8 kb band
corresponds to the knockin allele.
(C) Western blot analysis of ESCs. Lane 1: the
parental ESC line TC-1; lane 2: ESC line no. 10
(knockin of full-length Cbfb-MYH11), lanes 3 and
4: ESC lines no. 220 and no. 269 with knockin of
Cbfb-MYH11d179-221. The antibody used was the
mouse monoclonal antibody (b141.2) specific for
CBFb. The calculated molecular weights for
CBFb-SMHHC, CBFb-SMHHCd179-221, and CBFb
are 71 kDa, 65 kDa, and 22 kDa, respectively.
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icantly changed (Figures 3E, 3F). On the other hand, as we re-
ported before (Castilla et al., 1996), the number of colonies
generated from Cbfb+/MYH11 embryos was about 0%–1% of
the wild-type (Figures 3G, 3H). Overall the data suggest that
the hematopoietic defect was milder in the Cbfb+/MYH11d179-221
embryos than in Cbfb+/MYH11 embryos, and that the phenotype
of hemorrhage and embryonic lethality was partially rescued
by the HABD deletion.
Accelerated Leukemogenesis
in the Cbfb+/MYH11d179-221 Mice
The partial phenotypic rescue in the Cbfb+/MYH11d179-221
embryos was consistent with reduced repression of RUNX1.
We therefore predicted that the Cbfb+/MYH11d179-221 mice would
have reduced frequency or prolonged latency in leukemogen-
esis. Unexpectedly, all Cbfb+/MYH11d179-221 chimeras (n = 22)
died of leukemia by 19 weeks of age with no ENU (N-ethyl-N-
nitrosourea) treatment (Figure 4A), and the 2 surviving heterozy-
gous F1 mice (Figure 3A) developed leukemia even faster, at
10 and 18 days after birth, respectively. As a comparison,
Cbfb+/MYH11 chimeras (n = 17) did not develop leukemia sponta-
neously at similar ages (Figure 4A).458 Cancer Cell 17, 455–468, May 18, 2010 ª2010 Elsevier Inc.Histologically the leukemic cells in the
Cbfb+/MYH11d179-221 chimeras were either
poorly differentiated stem-like cells, or
myeloblasts (Figure 4B). Correspond-
ingly, by fluorescence-activated cell
sorting (FACS), a significant population
of the circulating leukemic cells was
c-Kit+, Mac-1, and Gr-1 (stem- or
progenitor-like cells), while another major
cell population was c-kit, Mac-1+, Gr-1+(myeloblasts) (Figures 4C and 4D). Interestingly, almost all
leukemic cells that were negative for Mac-1 and/or Gr-1
(either c-Kit+ or c-Kit) were positive for CD131 (Csf2rb), which
was also positive in almost all leukemic cells from mice ex-
pressing full-length Cbfb-MYH11 (Hyde et al., 2010). In addition,
the myeloblast population (c-Kit, Mac-1+, Gr-1+) in the
Cbfb+/MYH11d179-221 chimeras was significantly larger than that
in the Cbfb+/MYH11 chimeras (Figure 4E and data not shown).
The leukemic cells mainly infiltrated bone marrow (Figure 4B)
and spleen, as well as other organs such as liver and kidneys
(see Figure S1 available online), similar to what was observed
in the leukemic Cbfb+/MYH11 mice. Polymerase chain reaction
(PCR) was performed to confirm the ESC origin of the leukemic
cells (Figure 4F). In addition, CBFb-SMMHC protein products
of expected sizes were detected in the leukemic cells
(Figure 4G). Finally, sex-matched isogenic (C57BL/6 3 129/
Sv-F1) recipients were transplanted with leukemic spleen cells
(1 3 106 cells/mouse) from the Cbfb+/MYH11d179-221 chimeras.
The transplanted mice developed the same type of AML as that
of the donors 4 weeks after transplantation. Overall, the data
demonstrated that deleting the HABD did not reduce the leuke-
mogenic potential ofCbfb-MYH11. Instead, it led to acceleration
of leukemogenesis in the Cbfb+/MYH11d179-221 knockin mice.
Figure 3. Partial Phenotypic Rescue in
Cbfb+/MYH11d179-221 Heterozygous Embryos
(A) Genotype and phenotype of embryos derived
from crosses between Cbfb–MYH11 chimeras
and normal females. +/+ are wild-type littermates,
+/d179-221 are embryos heterozygous for Cbfb-
MYH11d179-221 knockin. Viability was determined
by embryo heart beats.
(B–D) Histologic sections of fetal livers from
E12.5 embryos. (B) wild-type control, (C)
Cbfb+/MYH11d179-221, (D) Cbfb
+/MYH11. Sections
were stained with H&E. Yellow arrows indicate
hematopoietic cells in the livers. Blue arrows
indicate megakaryocytes. Scale bars represent
100 mm.
(E–H) In vitro differentiation assay of fetal liver
hematopoietic cells. (E) and (F) compare colony
numbers from embryos of wild-type (black bars)
and Cbfb+/MYH11d179-221 (gray bars). (G) and (H)
compare colony numbers from embryos of wild-
type (black bars) and Cbfb+/MYH11 (gray bars). (E)
and (G): total colony numbers. BFU-E, burst-
forming unit-erythroid; CFU-E, colony-forming
unit-erythroid; CFU-G, colony-forming unit-granu-
locyte; CFU-GM, colony-forming unit-granulocyte/
macrophage; CFU-GEMM, colony-forming unit-
granulocyte/erythroid/macrophage/megakaryocyte;
CFU-M, colony-forming unit macrophage. The error
bars represent one SD. **p < 0.001.
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in Human CD34+ Cells
Recently we established a human CD34+ culture system to char-
acterize the effect of CBFb-SMMHC on human hematopoietic
stem and progenitor cells. We found that expressing full-length
CBFb-SMMHC initially repressed progenitor activity in methyl-
cellulose assays but eventually led to clonal expansion and the
establishment of long-term cell lines (Wunderlich et al., 2006).
To assess the effects of the HABD deletion, we introduced
CBFb-SMMHCd179-221 and CBFb-SMMHCd134-226 into human
CD34+ cells by retroviral transduction and analyzed the trans-
duced cells as described previously (Wunderlich et al., 2006).Cancer Cell 17, 455–4Total colony numbers were significantly
decreased initially in the cultures trans-
duced by either CBFb-SMMHC or the
deletion mutants, as compared with
vector alone (Figure 5A). This was associ-
ated with a significant decrease in the
number of BFU-E colonies, but relatively
increased proportion of GEMM and GM
colonies (Figure 5B). These data showed
that the effects of the deletion mutants on
human progenitor cells were similar to
that of CBFb-SMMHC (Wunderlich
et al., 2006). The transduced cells were
then kept in long-term liquid cultures
and were fed every 4th day. Beginning
at week 4, the percentage of cells ex-
pressing the deletion mutants gradually
increased in number, as did the cells
expressing CBFb-SMMHC (Wunderlichet al., 2006), and eventually grew robustly (data not shown). In
contrast, those cells transduced with the empty vector grew
slower over time and stopped expanding due to terminal differ-
entiation by 10-12 weeks. Long-term cultures were established
from the cells transduced with the deletion mutants as well
as with CBFb-SMMHC (Wunderlich et al., 2006). Cells at week
10 showed abnormal cellular morphology consistent with imma-
ture myelomonocytic cells at multiple stages of differentiation,
similar to cells transduced by CBFb-SMMHC (Figure 5C).
These results demonstrate that CBFb-SMMHCd179-221 and
CBFb-SMMHCd134-226, like full-length CBFb-SMMHC (Wunder-
lich et al., 2006), are able to promote the expansion of human68, May 18, 2010 ª2010 Elsevier Inc. 459
Figure 4. Acute Myeloid Leukemia Development in Cbfb+/MYH11d179-221 and Cbfb
+/MYH11 Chimeras
(A) Survival curves of Cbfb+/MYH11d179-221 and Cbfb
+/MYH11 chimeras. Dotted line: the survival curve of Cbfb+/MYH11 chimeras (n = 17); solid line: the survival curve
of Cbfb+/MYH11d179-221 chimeras (n = 22). The mice were not treated with any mutagens such as ENU.
(B) Morphology of leukemic cells in the Cbfb+/MYH11d179-221 mice. Left panel: Wright-Giemsa-stained peripheral blood smears showing poorly differentiated stem
cell-like cells (arrowheads) and myeloblasts (arrows). Middle and right panels: H&E-stained bone marrow sections from mice of the indicated genotypes. Scale
bar in the left panel represents 10 mm; those in the middle and right panels represent 50 mm.
(C) FACS analysis of peripheral blood cells in a Cbfb+/MYH11d179-221 mouse using antibodies against c-Kit, Mac-1, Gr-1, CD131, B220, CD4, and CD8.
(D) Correlation between cell morphology and surface marker expression for leukemic cells from the Cbfb+/MYH11d179-221 mice. FACS sorted c-kit
+/GR1/Mac1
and c-Kit/Gr1+/Mac1+ populations from mice of the indicated genotypes were analyzed for morphologic features through Wright-Giemsa staining of cytospin
preparations. Scale bars represent 10 mm.
(E) The percentages of leukemia cells expressing c-Kit or Gr-1/Mac1 in the Cbfb+/MYH11 and Cbfb+/MYH11d179-221 mice (n = 5 for each genotype) as detected by
FACS. The error bars represent one SD.
(F and G) Expression of the knocked in fusion genes in the leukemia cells. (F) RT-PCR with RNA samples from ESCs (lanes 1–4) and leukemic cells (lanes 5–7) with
PCR primers flanking theCbfb andMYH11 fusion junctions inCbfb-MYH11 andCbfb-MYH11d179-221. Lane 1: ESC line TC1; lane 2: ESC clone no. 10 with knockin
ofCbfb-MYH11; lanes 3 and 4: ESC lines nos. 220 and 269 with knockin ofCbfb-MYH11d179-221; lane 5: leukemia cells from aCbfb
+/MYH11 chimera; lanes 6 and 7:
leukemia cells from two Cbfb+/MYH11d179-221 chimeras. (G) Western blot analysis with protein samples from leukemic cells of the indicated genotype and the
CBFb-specific antibody (b141.2).
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Figure 5. Growth and Differentiation Defects of Human CD34+ Cells Transduced with CBFB-MYH11 Variants
(A and B) In vitro differentiation of human CD34+ cells. Human CD34+ cells were transduced with empty retroviral vector (MIG), and vectors expressing
CBFB-MYH11 (FL), CBFB-MYH11d179-221 (d179-221), or CBFB-MYH11d134-236 (d134-236). The transduced cells were sorted by FACS and 2000 GFP
+ cells
were plated in serum-free methylcellulose cultures. (A) Total colony numbers scored after 14 days. The total colony number from MIG-transduced cells was
set at 1, and the total colony numbers from the other two transduced cell populations were calculated relative to that of MIG. The data shown are averages
of three independent experiments. (B) Frequencies of BFU-E, CFU-GM, and CFU-GEMM colonies from transduced human CD34+ cells. The data shown are
averages of two independent experiments. *p < 0.01 between clones transduced with MIG and those with CBFB-MYH11 constructs; **p < 0.001 between clones
transduced with MIG and those with CBFB-MYH11 constructs. The error bars represent one SD.
(C) Cell morphology from long-term cultures of human CD34+ cells transduced with CBFB-MYH11 or CBFB-MYH11d179-221. Shown are cytospin preparations of
nonadherent cells at week 10, stained with Wright-Giemsa stain. Scale bars represent 10 mm.
(D) Western blot analysis with protein samples from transduced human CD34+ cells and the CBFb-specific antibody (b141.2).
Cancer Cell
Leukemogenesis by Truncated CBFb-SMMHCCD34+ progenitor cells in vitro. Figure 5D shows a representative
western blot that the fusion proteins were expressed at similar
levels in the CD34+ cell lines.
Upregulation of MN1 in Cells Expressing
CBFb-SMMHCd179-221
We performed quantitative real-time (qRT) PCR to assess the
expression level of five genes previously shown to be altered
in CBFb-SMMHC-transformed human patient samples. We
found similar expression alterations for all five genes in human
CD34+ cells expressing CBFb-SMMHCd179-221 when compared
with normal human CD34+ cells (Figure 6A). Specifically,
NRP1, SPARC, and CLIPR-59 were all upregulated, while
RUNX3 was downregulated in CBFb-SMMHCd179-221 express-
ing cells. The expression changes for these four genes were
not significantly different from those in CBFb-SMMHC express-
ing cells. Interestingly, MN1 was significantly increased in
CBFb-SMMHCd179-221 compared with both full-length
CBFb-SMMHC and the control (Figure 6A).
We have shown previously that MN1 is overexpressed in
many human inv(16) AML cells and that MN1 cooperates with
CBFB-MYH11 for leukemogenesis in mouse models (Carellaet al., 2007). Higher expression level of MN1 observed in human
CD34+ cells expressing CBFb-SMMHCd179-221 may explain why
CBFb-SMMHCd179-221 could induce leukemia more efficiently in
the knockin mice. We therefore determined the expression level
of MN1 protein in leukemia cells from the CBFb-SMMHCd179-221
and CBFb-SMMHC chimeras. The results showed that MN1 was
expressed at higher levels in the CBFb-SMMHCd179-221 mice
than in the CBFb-SMMHC mice (Figure 6B).
We also performed microarray analysis of gene expression
changes in the leukemic cells isolated from spleens of
Cbfb+/MYH11d179-221 and Cbfb
+/MYH11 chimeras with AML. We
detected significant changes in gene expression between
leukemia cells of the two genotypes in several pathways using
Ingenuity Pathway Analysis (IPA, data not shown). Notably, the
network with the highest score (IPA score = 54) was centered
on Cebpa, with most of the genes in this network upregulated
in theCbfb+/MYH11d179-221mice, includingCebpa itself (Figure 6C;
more detailed information about the genes in this network is
available in Table S1). As predicted based on the function of
Cebpa, many genes in this network are related to functions in
more mature myeloid cells. These results suggest that leukemia
cells in the CBFb-SMMHCd179-221 mice were more differentiatedCancer Cell 17, 455–468, May 18, 2010 ª2010 Elsevier Inc. 461
Figure 6. Similar Gene Expression Changes Induced by CBFB-MYH11 and CBFB-MYH11d179-221
(A) qRT-PCR analysis of RNA samples from human CD34+ cell transduced with MIG, CBFB-MYH11, and CBFB-MYH11d179-221. Error bars represent SDs of
two to six samples. *p < 0.05 between MIG and CBFB-MYH11 or CBFB-MYH11d179-221; **p < 0.01 between MIG and CBFB-MYH11 or CBFB-MYH11d179-221;
:p < 0.05 between CBFB-MYH11 and CBFB-MYH11d179-221. The error bars represent one SD.
(B) Western blot detection of MN1 expression in leukemia cells from Cbfb+/MYH11 and Cbfb+/MYH11d179-221 mice.
(C) Overexpression of myeloid genes in the Cebpa network from analysis of microarray data by IPA. The blue arrows highlight connections directly from Cebpa.
Pink colored genes are those that upregulated. More detailed information about the genes in this network is available in Table S1.
(D) The Mn1 network identified by IPA analysis of microarray data. More detailed information about the genes in this network is available in Table S2.
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ical findings (Figures 4B–4E).
Mn1 did not pass the cutoff IPA score, probably because its
RNA level was too low. Therefore it was not included in the initial
IPA analysis. In order to determine gene expression networks
affected by Mn1, we added Mn1 to the data set manually with
an arbitrary assignment of 2-fold upregulation (because we
know through other approaches described above that it was
upregulated in the leukemia cells). The IPA analysis assigned
MN1 to a pathway that includes Tgfbeta1, Tcf4 (both were
upregulated), and Mllt3 (downregulated) (Figure 6D; more462 Cancer Cell 17, 455–468, May 18, 2010 ª2010 Elsevier Inc.detailed information about the genes in this network is available
in Table S2). This network has a score of 28 (no. 6 on the score
list) and the top functions assigned to the network are cellular
assembly and organization, endocrine system disorders, and
tissue morphology.
RUNX1 Phosphorylation in Cells Expressing
CBFb-SMMHCd179-221
Phosphorylation of RUNX1 at serine residues 249, 276, and 303
has been demonstrated to play important roles for its degrada-
tion, transactivation, and functions in cell cycle (Aikawa et al.,
Figure 7. RUNX1 and p300 Phosphorylation
(A) RUNX1 phosphorylation by CBFb and deletion variants of CBFb-SMMHC.
CBFb, CBFb-SMMHC, or deletion variants of CBFb-SMMHC fusion proteins
were coexpressed in 293T cells with RUNX1 and wild-type p300. Western
blot analyses were performed using the indicated antibodies.
(B) p300 phosphorylation by CBFb and deletion variants of CBFb-SMMHC
fusion proteins. Wild-type p300 or mutant p300 (p300DSTP1,2,3) were trans-
fected with RUNX1 and CBFb, CBFb-SMMHC, or the CBFb-SMMHC deletion
constructs. Immunoblotting with p300 antibody was performed with lysates
from transiently transfected 293T cells.
(C) RUNX1 phosphorylation in human and mouse leukemia samples. ME1, a
cell line derived from an inv(16)+ AML case (Yanagisawa et al., 1991); primary,
primary leukemia cells from bone marrow of an inv(16)+ AML case (Liu et al.,
1996). Both human cases contain the type A CBFB-MYH11 fusion. FL, full-
length CBFb-SMMHC, D43, CBFb-SMMHCd179-221; WT BM, wild-type whole
bone marrow cells after erythrocyte lysis. Protein lysates were isolated
from human and mouse leukemic cells, and western blot analyses were
performed using the indicated antibodies.
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Leukemogenesis by Truncated CBFb-SMMHC2006; Biggs et al., 2006; Wee et al., 2008; Zhang et al., 2008).
HIPK2 phosphorylates RUNX1 at Ser249 and Ser276 in
a CBFb-dependent manner, which in turn leads to phosphoryla-
tion of p300 (Aikawa et al., 2006; Wee et al., 2008). Interestingly
CBFb-SMMHC disrupts the phosphorylation of both RUNX1 andp300, which have been proposed as a potential mechanism for
leukemogenesis by CBFb-SMMHC (Wee et al., 2008). In addi-
tion, cyclin-dependent kinase phosphorylation of RUNX1 at
three sites (including Ser303) has been shown to regulate
RUNX1 degradation (Biggs et al., 2006), increase RUNX1 trans-
activation potency, and stimulate cell proliferation (Zhang et al.,
2008). We therefore decided to investigate the effect of
CBFb-SMMHCd179-221 on RUNX1 phosphorylation.
As shown in Figures 7A and 7B, we confirmed that
CBFb-SMMHC repressed RUNX1 and p300 phosphorylation,
when the proteins were overexpressed in transient transfection
assays. However, both the type I fusion, CBFb-SMMHCd134-236,
and CBFb-SMMHCd179-221 were fully capable of promoting
RUNX1 and p300 phosphorylation in this assay, similar to wild-
type CBFb. Furthermore, when mouse leukemia cells that
express CBFb-SMMHC or CBFb-SMMHC d179-221 were exam-
ined, their RUNX1 phosphorylation levels seemed to be similar
to each other (Figure 7C). This was confirmed in human leukemia
cells with inv(16). As shown in Figure 7C, RUNX1 was phosphor-
ylated at all three serine residues in a primary leukemia
sample (Liu et al., 1996) as well as in the cell line ME1 (Yanagi-
sawa et al., 1991). These results suggest that RUNX1 was phos-
phorylated in the presence of CBFb-SMMHC after leukemic
transformation even though CBFb-SMMHC reduced RUNX1
phosphorylation in transient cell culture assays.
DISCUSSION
CBFb-SMMHC dominantly represses RUNX1 function, gener-
ates defects in definitive hematopoiesis (Castilla et al., 1996),
and predisposes mice to leukemia with cooperating gene
mutations (Castilla et al., 1999, 2004). In comparable mouse
models, the leukemia fusion gene RUNX1-ETO (also known as
AML1-ETO) functions very similarly: it dominantly suppresses
RUNX1 function, blocks hematopoiesis, and requires additional
‘‘hits’’ for leukemogenesis (Yergeau et al., 1997; Yuan et al.,
2001). Therefore, the hypothesis of RUNX1 inhibition as a
common leukemogenic pathway has been proposed for
CBF-related leukemias (Speck and Gilliland, 2002).
Previously we identified a RUNX1 high-affinity binding domain,
HABD, at a proximal region of SMMHC in the CBFb-SMMHC
fusion protein (Lukasik et al., 2002). The HABD has been consid-
ered as one of the most important domains for dominant
repression of RUNX1, because the domain makes it possible
for CBFb-SMMHC to outcompete CBFb for RUNX1 binding.
Clinically the fusion junctions between CBFB and MYH11 are
heterogeneous, ten different fusion junctions have been reported
(van Dongen et al., 1999). All other CBFB-MYH11 fusion types
contain the HABD except for the type I fusion. Earlier reports
suggested that type I fusion is rare and tends to be associated
with therapy related AML or myelodysplastic syndrome (Dissing
et al., 1998; Grardel et al., 2002; van der Reijden et al., 1995;
Yamamoto et al., 2006). But a more recent publication indicated
that type I fusion is potentially more frequent and can be associ-
ated with de novo AML (Monma et al., 2007). It is noticeable that
most commonly used RT-PCR primers for diagnosis of CBFB-
MYH11 would not be able to detect the type I fusion, so it may
have been under-diagnosed, especially in cytogenetically nega-
tive cases (Van der Reijden et al., 2001; van Dongen et al., 1999).Cancer Cell 17, 455–468, May 18, 2010 ª2010 Elsevier Inc. 463
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high-efficient RUNX1 repression is not always required for leuke-
mogenesis.
To understand the importance of HABD for leukemogenesis,
we generated mice expressing a knockin Cbfb-MYH11 fusion
gene with the HABD removed (Cbfb+/MYH11d179-221). In vitro
and in vivo analyses indicated that the encoded CBFb-
SMMHCd179-221 was less efficient in binding and repressing
RUNX1, as expected. Unexpectedly, leukemia development
was accelerated in the Cbfb+/MYH11d179-221 knockin mice, so
that all the chimeras and F1 heterozygotes developed leukemia
shortly after birth without ENU treatments. These findings cast
doubts on the model that strong, dominant repression of
RUNX1 is a key step in leukemogenesis.
Human CD34+ cells expressing the CBFb-SMMHC variants
behaved essentially the same as those expressing the full-
length. This finding is consistent with our conclusion that
RUNX1 dominant inhibition may not be a critical step for leuke-
mogenesis by CBFb-SMMHC. However, the CBFb-SMMHC
variants did not accelerate the phenotype development in the
human CD34+ cells, as compared with the accelerated leukemo-
genesis in the knockin mouse model. This difference is likely
related to the fact that transgenic expression from retroviral
vectors was used in the human CD34+ cells, whereas knockin
technology was used in the mouse model. Both alleles of
CBFB are intact in the human CD34+ cells; on the other hand,
one Cbfb allele in the mouse genome is replaced by the
Cbfb-MYH11 fusion gene. The endpoint of the human CD34+
cell assay system is also different from that in the mouse model,
being clonal expansion rather than leukemia. All these factors
could have contributed to the observed differences between
these two systems.
The mechanism for the accelerated leukemogenesis in the
Cbfb+/MYH11d179-221 mice is not clear. It is possible that the dele-
tion released an antileukemia effect or provided a leukemia-
promoting effect, such as upregulation of a cooperating gene.
One potential candidate is MN1, which was upregulated in
leukemia cells in the Cbfb+/MYH11d179-221 mice, as well as in
human CD34+ cells expressing CBFb-SMMHCd179-221. MN1 is
an important cooperating gene for inv(16) leukemogenesis, as
has been demonstrated by its specific upregulation in human
inv(16) leukemia and its ability to accelerate leukemogenesis in
our mouse Cbfb-MYH11 knockin model (Carella et al., 2007). It
is therefore plausible that CBFb-SMMHCd179-221 further upregu-
lates MN1, which in turn cooperates with CBFb-SMMHCd179-221
for leukemogenesis.
CBFb-SMMHCd179-221 may upregulate MN1 through multiple
mechanisms. First, it appears that both full-length and d179-
221 forms of CBFb-SMMHC are able to upregulate MN1 at the
level of transcription (Figure 6A). Second, at the protein level,
MN1 is recruited by p300 to act as a coactivator (van Wely
et al., 2003). It is likely that MN1 protein level/functionality is
enhanced in cells expressing CBFb-SMMHCd179-221 because
there is more p300 phosphorylation in these cells than in those
expressing full-length CBFb-SMMHC (Figure 7B). Third, hema-
topoietic blockage is less severe in the CBFb-SMMHCd179-221
mice, resulting in a larger population of myeloid progenitors in
the bone marrow (Figure 4E), which express the highest level
of MN1 (Grosveld, 2007). In summary, we believe the combined464 Cancer Cell 17, 455–468, May 18, 2010 ª2010 Elsevier Inc.effect of a larger population of cells expressing high baseline
level of MN1, more efficient p300 recruitment, and the transcrip-
tional upregulation contributes to higher expression level of MN1
in cells with CBFb-SMMHCd179-221.
The finding that the type I fusion and CBFb-SMMHCd179-221
are fully capable of promoting RUNX1 and p300 phosphoryla-
tion, in contrast to CBFb-SMMHC, is interesting. However,
because this activity is similar to wild-type CBFb, it raises the
question as how this would contribute to the enhanced leukemo-
genic activity.
A likely explanation is that RUNX1 phosphorylation is a modi-
fying or cooperating step, which contributes to leukemogenesis
only in the presence of CBFb-SMMHC proteins. More
RUNX1 and p300 phosphorylation in mice expressing CBFb-
SMMHCd179-221 is consistent with partial rescue of hematopoi-
etic blockage in these mice. It is therefore not surprising that
this activity is similar to wild-type CBFb, because CBFb supports
rather than blocks RUNX1 function in hematopoiesis.
The implications of normal Runx1 phosphorylation and
hematopoietic rescue in the CBFb-SMMHCd179-221 mice are at
least 2-fold. First, normal Runx function may be required for
leukemogenesis. We have observed that reduction of RUNX1
activity by introducing a Runx1 dominant negative allele to the
Cbfb+/MYH11 mice delayed leukemia development (L.Z. and
P.P.L., unpublished data). It was also shown recently that
RUNX2 cooperated with CBFb-SMMHC for leukemogenesis
(Kuo et al., 2009). Second, reduced blockage of hematopoiesis
as a result of partial RUNX1 inhibition may have led to the
expansion of a ‘‘leukemia-prone’’ cell population, which
provides more ‘‘target’’ cells for leukemogenesis. We speculate
that HSCs were the target cells in the Cbfb+/MYH11 mice whereas
both HSCs and myeloid progenitors could be the target cells in
the Cbfb+/MYH11d179-221 mice. The fact that more leukemia cells
in the Cbfb+/MYH11d179-221 mice express myeloid markers (Fig-
ure 4E) suggests that leukemia may have initiated in myeloid
progenitors in these mice.
Our finding that partial inhibition of RUNX1 may be more
leukemogenic than complete RUNX1 inhibition is similar to
what happened with PU.1, a hematopoietic transcription factor
downstream of RUNX1. Mice with homo- or heterozygous dele-
tion of Pu.1 do not develop leukemia; on the other hand, mice
carrying hypomorphic alleles of Pu.1 with reduced expression
(20% of normal) developed AML rapidly and efficiently (Rose-
nbauer et al., 2004).
Moreover, a variant of the AML1-ETO fusion protein, AML1-
ETO9a that contains C-terminal truncation, was found to be a
much more potent inducer of leukemia than the full-length
AML1-ETO in mouse models. It has been hypothesized that
the deleted region inhibits the leukemogenic potential of
AML1-ETO (Peterson et al., 2007). Interestingly AML1-ETOtr, a
C-terminally truncated protein similar to AML1-ETO9a, lost the
ability to inhibit cell cycle progression of myeloid cells, which
may contribute to its enhanced leukemogenic potential (Yan
et al., 2004). This AML1-ETO variant is thus similar to the
CBFb-SMMHC179-221 variant reported here, in that they are
both less potent in repressing RUNX1/CBFB function yet are
more potent in leukemogenesis.
Recent results (Kwok et al., 2009; Park et al., 2009; Roudaia
et al., 2009) show that while very modest effects on the
Figure 8. Working Model for Leukemogen-
esis in Cbfb+/MYH11d179-221 Mice
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leukemogenesis, substantial loss of binding results in a protein
that is incapable of causing leukemia, likely a reflection of the
relatively high concentration of CBFb in cells. This point is
echoed by recent studies on recurrent mutations in RUNX1 in
patients with AML subtype M0 and familial platelet disorder
with predisposition to AML. The mutations abolish DNA binding
and transactivation by RUNX1 in vitro (Michaud et al., 2002;
Osato et al., 1999) and cause hematopoietic defects and embry-
onic lethality in mice (Matheny et al., 2007), suggesting that they
are mostly loss-of-function mutations. However, it was recently
shown that these mutations also altered differentiation and
increased serial replating ability (Cammenga et al., 2007), indi-
cating that RUNX1 has DNA-binding independent activities
that play a role in leukemogenesis. Because the primary role of
CBFb is to stabilize RUNX1’s interaction with DNA, these find-
ings provide further argument for CBFB/RUNX repression inde-
pendent mechanisms in leukemogenesis.Cancer Cell 17, 455–4Our current model for leukemogenesis
in the Cbfb+/MYH11d179-221 mice is illus-
trated in Figure 8. More severe blockage
of hematopoiesis and RUNX1 inhibition
by Cbfb-MYH11 results in a smaller
leukemia target cell pool, where additional
mutations are needed to introduce coop-
erating genes and to restore RUNX1
phosphorylation. On the other hand,
a larger population of leukemia target cells
is available in the Cbfb+/MYH11d179-221
mice, and leukemogenesis is further
accelerated by upregulation of MN1 and
retention of RUNX1 phosphorylation.
In summary, loss of the HABD from
CBFb-SMMHC unexpectedly potenti-
ated its leukemogenic activity, raising
questions to the proposed dominant-
negative mechanism of leukemogenesis.
Partial reduction of key transcription
factors such as RUNX1 and PU.1 may
be a common mechanism for leukemo-
genesis. Moreover, CBFb-SMMHC may
contribute to leukemogenesis through
pathways other than RUNX1 repression.
Recent work from our group has provided
evidence for such RUNX1 repression
independent pathways (Hyde et al.,
2010). However, it still needs to be deter-
mined whether the leukemogenic activi-
ties of CBFb-SMMHC depend on its
interaction with RUNX1, even for those
that do not seem to require RUNX1-
repression. Such studies will provide
important mechanistic insight guiding
the design and development of smallmolecule inhibitors targeting the CBFb/AML1 interaction for
leukemia treatments (Gorczynski et al., 2007).
EXPERIMENTAL PROCEDURES
ESC Targeting and Mouse Experiments
The targeting constructs were assembled in the pPNT vector, which included
a thymidine kinase gene as positive selection. A 3.5 kb KpnI–StuI mouse
genomic clone (strain 129/Sv), including mouse Cbfb intron 4 and the first
25 bp of mouse exon 5, was ligated to the StuI site of a 1.5 kb StuI–NotI human
CBFB–MYH11 cDNA clone or a mutant CBFB–MYH11 cDNA with HABD dele-
tion from aa 179 to 221. The PGK neo was ligated downstream of BGHpA.
A 4.7 kb mouse genomic clone ofCbfb intron 5 (strain 129/Sv) was then ligated
to the 30 end of the PGK neo fragment. The constructs were linearized at a NotI
site and transfected into the TC 1 ESCs (from mouse strain 129/SvEv).
Screening of the targeted ESC clones by Southern blot analysis was per-
formed as described elsewhere (Castilla et al., 1996; Kuo et al., 2006). ESCs
were injected into C57BL/6-derived blastocysts. Chimeric mice were crossed
with C57BL/6 females for further embryo analysis. The mouse studies were
approved by the NHGRI Animal Care and Use Committee, and all experiments68, May 18, 2010 ª2010 Elsevier Inc. 465
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lines and regulations.
Western Blot Analysis
Protein isolation, gel electrophoresis, blot transfer, and detection with mono-
clonal antibody b141.2 and actin (Millipore) were performed as described
previously (Kundu et al., 2002).
Histological Sections
E12.5 embryos and adult tissues (such as liver, kidney, and spleen) were fixed
in 10% formalin and the sections were stained with either Wright-Giemsa or
hematoxylin and eosin (H&E) stains (American HistoLabs, Inc., Gaithersburg,
MD). The histopathology slides were examined and photographed as
described (Castilla et al., 1999).
In Vitro Differentiation Experiments for Fetal Liver
Fetal liver cells from E11.5 embryos were isolated and cultured in methylcellu-
lose medium M3434 (StemCell Technologies, Inc., Vancouver, Canada).
Colonies were scored at day 7 as described before (Castilla et al., 1996).
Flow Cytometry Analysis
Peripheral blood and leukemic spleen cells were stained with PE-TexRed-
B220, PE-Ter119, PE-Cy7-GR1, APC-Cy7-C-kit, PerCp-Cy5.5-Mac1, Pacific
Blue-CD4, APC-CD8 (BD Biosciences PharMingen, CA) for flow cytometry
analysis. Appropriate isotype controls were used in each experiment. LSRII
(BD Biosciences, CA) was used to acquire data, which were analyzed using
Flowjo 9.0.1 (Tree Star, Inc., Ashland, OR).
RNA Isolation and RT-PCR
Total RNA was isolated from ESCs and leukemic cells using RNA STAT-60
(TEL-TEST, INC.). The presence of the Cbfb–MYH11 transcript was identified
using a forward primer that is in exon 3 of the mouse Cbfb gene (E3: 50-CAA
ACA CCT AGC CGG GAA TA-30) and a reverse primer in the human MYH11
cDNA (MYH11: 50-CTT CCA AGC TCT TGG CTT TCT TC-30). The quality
of the reverse-transcribed cDNA was confirmed by PCR using primer
mC3/4.1F and a reverse primer in exon 6 of the mouse Cbfb gene (mC6.1R:
50-GAACCAGGACTAGGGTCTTGC-30). In all instances, PCR conditions
were the same as those for genotype analysis described below.
Genotype Analysis
The presence of the knockin alleles was assessed by PCR using DNA isolated
from tail snips, PB, yolk sacs, ESCs or whole embryos. We amplified 50 ng
template DNA by PCR using neo-specific primer (neo forward 50-AGAGGCT
ATTCGGCTATGA CTG-30, and neo reverse 50TTCGTCCAGATCATCCTG
ATC-30). The PCR cycle conditions were 94C for 2 min, 30 cycles of amplifi-
cation (30 s each at 94C, 60C, and 72C), and a final 5 min extension step at
72C. The genotypings were confirmed in a parallel PCR reaction with
a forward primer in exon 5 of the mouse Cbfb gene (E5: 50-CAG GAA GAT
GCA TTA GCA CAA-30) and the reverse primer MYH11.
Human CD34+ Cell Assays
Human CD34+ umbilical cord blood cells were obtained from the Translational
Research Development and Support Laboratory of Cincinnati Children’s
Hospital under an approved IRB protocol. Retroviral production, transduction,
cell culture, CFU assays, and qRT-PCR were performed as previously
described (Wunderlich et al., 2006).
Microarray Analysis
Spleen cells were isolated from knockin mice with AML, including two
adult Cbfb+/MYH11 chimeras at 2 months after ENU treatment and two
Cbfb+/MYH11d179-221 chimeras at 3 weeks after birth. For each sample we per-
formed two independent experiments with Affymetrix GeneChip 430. All inten-
sity values were scaled to an average value of 150 per GeneChip according
to the method of global scaling, or normalization, provided in the Affymetrix
Microarray Suite software. The normalized results were then analyzed using
Genesifter (VizX Labs, Seattle, WA).466 Cancer Cell 17, 455–468, May 18, 2010 ª2010 Elsevier Inc.Expression and Purification of CBFb-SMMHCd134-236
CBFb-MYH11d134-236 was cloned in the pHis-parrallel vector (Sheffield et al.,
1999). CBFb-SMMHCd134-236 was expressed in Rosetta (DE3) cells after
induction with IPTG and purified with a Ni-NTA column (QIAGEN, Valencia,
CA). The 6xHis-tag was cleaved with the AcTEV protease (Invitrogen,
Carlsbad, CA). Further purification of the protein was accomplished using
ion-exchange chromatography on a Q-Sepharose (GE Healthcare, Piscat-
away, NJ).
Isothermal Titration Calorimetry
ITC measurements were carried out at 30C on a VP-ITC MicroCalorimeter
system (MicroCal Inc., Northampton, MA). Protein samples were dialyzed
against 12.5 mM KPi (pH 6.5), 150 mM NaCl, 2.5 mM MgCl2, and 1 mM
DTT, centrifuged to remove precipitates, and degassed for 15 min prior to
use. A total of 15 mM RUNX1 Runt Domain was titrated with 200 mM
CBFb-SMMHCd134-236. Dilution enthalpies were determined through protein
into buffer experiments, and were subtracted from the initial experiments.
Data were analyzed using Origin 7.0 (Origin Lab, Northampton, MA).
In Vitro Reporter Assay
CAT reporter assay was performed as described before (Zhao et al., 2007).
Briefly, the CAT reporter constructs were transfected into the CD4- Jurkat
cell clone (D1.1, from American Type Culture Collection, Manassas, VA) alone
or with RUNX1, CBFB, CBFB-MYH11, CBFB-MYH11d179-221, and CBFB-
MYH11d134-236 cDNA constructs by electroporation (BTX electroporation
system, Harvard Apparatus, Holliston, MA). CAT activity was measured
following manufacture’s protocol (CAT ELISA, Roche Diagnostics, Basel,
Switzerland). A luciferase vector was cotransfected to standardize transfec-
tion efficiency. The transfection was performed three times with similar results.
For the MCSFR reporter assay, 293T cells were seeded into 6-well plates
(5 3 105 cells/well) 1 day before transfection. Then 1.2 mg pMCSFR-luc
(Rhoades et al., 1996), and 1 mg RUNX1, CBFB, CBFB-MYH11, CBFB-
MYH11d179-221, and CBFB-MYH11d134-236 were transfected using Lipofecta-
min 2000 (Invitrogen). The experiments were performed three times.
RUNX1 and p300 Phosphorylation
Typically, 105 293 cells were plated in 6-well plate and cultured overnight
before transiently transfected with expression constructs for RUNX1 (0.1 mg),
CBFb or each CBFb-SMMHC truncated mutant (0.3 mg), and with p300(0.5 mg),
using the FuGENE 6 reagent (Roche Diagnostics, Indianapolis, IN)
according to manufacturer’s instructions. The expression constructs for
pEF-neo-RUNX1, pEF-bos-CBFb, pEF-bos-Full length CBFb-SMMHC,
CBFb-SMMHC d179-221, and CBFb-SMMHCd134-236 were described previously
(Huang et al., 2001). pcDEF-FLAG-p300 and pcDEF-FLAG-p300DSTP1,2,3 were
also described previously (Wee et al., 2008).
Lysates from transiently transfected 293T cells were subjected to SDS-
PAGE and transferred to polyvinylidene difluoride membranes (Bio-Rad,
Hercules, CA). After probing with appropriate antibodies, protein bands
were detected using the enhanced chemiluminescence detection system
(GE Healthcare). The following primary antibodies were used in the study.
Rabbit anti-AML1 (Active Motif, Carlsbad, CA), Phospho-AML1 Ser249 (Cell
Signaling, MA), RUNX1/AML1 phospho S276 antibody ab55291 (Abcam,
MA), RUNX1/AML1 phospho S303 antibody ab55308 (Abcam), and anti-
p300 antibody (N15) (Santa Cruz Biotechnology, CA). Secondary horseradish
peroxidase-linked goat anti-rabbit IgG or anti-mouse antibodies used in
western blotting were obtained from GE Healthcare (Little Chalfont, UK).
ACCESSION NUMBERS
The microarray data have been deposited in the Nation Center for Biotech-
nology Information’s Gene Expression Omnibus database with the accession
number GSE21155.
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